Specifically, bevacizumab, alone or in combination with chemotherapy or radiation, has been associated with increased tumor infiltration by activated effective T cells coupled to Treg and TAM depletion [109], improved DC maturation [110], and downregulation of PD-L1 on malignant and myeloid cells in preclinical cancer models [111]. Here, CD274 is linked to neoplasm.